Long-term administration of fasudil improves cardiomyopathy in streptozotocin-induced diabetic rats

Food and Chemical Toxicology

Volumn 50, Issue 6, 2012, Pages 1874-1882

  Guan, Sheng jiang ^a   Ma, Zhi hong ^a   Wu, Yan ling ^b   Zhang, Jian ping ^a   Liang, Feng ^c   Woodrow Weiss, J ^c   Guo, Qian yu ^a   Wang, Jiang yan ^d   Ji, En sheng ^a   Chu, Li ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Department of Pharmacy   (China)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Bethune Military Medical College   (China)

Author keywords

Diabetic cardiomyopathy; Fasudil; Rho kinase; Streptozotocin

Indexed keywords

CAPTOPRIL; COLLAGEN; CREATINE KINASE; FASUDIL; LACTATE DEHYDROGENASE; MALONALDEHYDE; PROTEIN BAX; PROTEIN BCL 2; RHO KINASE; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; GENE EXPRESSION; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID PEROXIDATION; LONG TERM CARE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIOXIDANTS; APOPTOSIS; BLOOD GLUCOSE; BODY WEIGHT; CAPTOPRIL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; ENZYME INHIBITORS; HEMODYNAMICS; IN SITU NICK-END LABELING; MALE; MALONDIALDEHYDE; MICROSCOPY, ELECTRON, TRANSMISSION; MYOCARDIUM; ORGAN SIZE; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; SUPEROXIDE DISMUTASE;

RATTUS;

EID: 84860142048     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.03.006     Document Type: Article

References (50)

1. Asano T., Ikegaki I., Satoh S., Suzuki Y., Shibuya M., Takayasu M., Hidaka H. Mechanism of action of a novel antivasospasm drug, HA1077. J. Pharmacol. Exp. Ther. 1987, 241:1033-1040.
2. Boudina S., Abel E.D. Diabetic cardiomyopathy revisited. Circulation 2007, 115:3213-3223.
3. Budzyn K., Marley P.D., Sobey C.G. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol. Sci. 2006, 27:97-104.
4. Cai L., Kang Y.J. Oxidative stress and diabetic cardiomyopathy. Cardiovasc. Toxicol. 2001, 1:181-193.
5. Cesselli D., Jakoniuk I., Barlucchi L., Beltrami A.P., Hintze T.H., Nadal-Ginard B., Kajstura J., Leri A., Anversa P. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ. Res. 2001, 89:279-286.
6. Depre C., Young M.E., Ying J., Ahuja H.S., Han Q., Garza N., Davies P.J.A., Taegtmeyer H. Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J. Mol. Cell. Cardiol. 2000, 32:985-996.
7. Dhalla N.S., Liu X., Panagia V., Takeda N. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc. Res. 1998, 40:239-247.
8. Fang Z.Y., Prins J.B., Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 2004, 25:543-567.
9. Frustaci A., Kajstura J., Chimenti C., Jakoniuk I., Leri A., Maseri A., Nadal-Ginard B., Anversa P. Myocardial cell death in human diabetes. Circ. Res. 2000, 87:1123-1132.
10. Fukushima M., Nakamuta M., Kohjima M., Kotoh K., Enjoji M., Kobayashi N., Nawata H. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int. 2005, 25:829-838.
11. Funakoshi Y., Ichiki T., Shimokawa H., Egashira K., Takeda K., Kaibuchi K., Takeya M., Yoshimura T., Takeshita A. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 2001, 38:100-104.
12. Gheorghiade M., De Luca L., Bonow R.O. Neurohormonal inhibition in heart failure: insights from recent clinical trials. Am. J. Cardiol. 2005, 96(Suppl. 12A):3L-9L.
13. Gojo A., Utsunomiya K., Taniguchi K., Yokota T., Ishizawa S., Kanazawa Y., Kurata H., Tajima N. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 2007, 568:242-247.
14. Hattori T., Shimokawa H., Higashi M., Hiroki J., Mukai Y., Tsutsui H., Kaibuchi K., Takeshita A. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 2004, 109:2234-2239.
15. Higashi M., Shimokawa H., Hattori T., Hiroki J., Mukai Y., Morikawa K., Ichiki T., Takahashi S., Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo, effect of endothelial NAD(P)H oxidase system. Circ. Res. 2003, 93:767-775.
16. Hiroki J., Shimokawa H., Higashi M., Morikawa K., Kandabashi T., Kawamura N., Kubota T., Ichiki T., Amano M., Kaibuchi K., Takeshita A. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J. Mol. Cell. Cardiol. 2004, 37:537-546.
17. Hisaoka T., Yano M., Ohkusa T., Suetsugu M., Ono K., Kohno M., Yamada J., Kobayashi S., Kohno M., Matsuzaki M. Enhancement of Rho/Rho-kinase system in regulation of vascular smooth muscle contraction in tachycardia-induced heart failure. Cardiovasc. Res. 2001, 49:319-329.
18. Hoyt R.H., Erickson E., Collins S.M., Skorton D.J. Computer-assisted quantitation of myocardial fibrosis in histologic section. Arch. Pathol. Lab. Med. 1984, 108:280-283.
19. Huang L., He Z., Guo L., Wang H. Improvement of cognitive deficit and neuronal damage in rats with chronic cerebral ischemia via relative long-term inhibition of Rho-kinase. Cell. Mol. Neurobiol. 2008, 28:757-768.
20. Inoguchi T., Li P., Umeda F., Yu H.Y., Kakimoto M., Imamura M., Aoki T., Etoh T., Hashimoto T., Naruse M., Sano H., Utsumi H., Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000, 49:1939-1945.
21. Ishizaki T., Maekawa M., Fujisawa K., Okawa K., Iwamatsu A., Fujita A., Watanabe N., Saito Y., Kakizuka A., Morii N., Narumiya S. The small GTP-binding protein Rho binds to and activates a 160kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996, 15:1885-1893.
22. Kaul N., Siveski-Iliskovic N., Thomas T.P., Hill M., Khaper N., Singal P.K. Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition 1995, 11(5 Suppl.):551-554.
23. Kikuchi Y., Yamada M., Imakiire T., Kushiyama T., Higashi K., Hyodo N., Yamamoto K., Oda T., Suzuki S., Miura S. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J. Endocrinol. 2007, 192:595-603.
24. Kolavennu V., Zeng L., Peng H., Wang Y., Danesh F.R. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008, 57:714-723.
25. Krishna K.M., Gopal G.S., Chalam C.R.V., Madan K., Kumar V.K., Prakash G.J., Annapurna A. The influence of sulindac on diabetic cardiomyopathy: a non-invasive evaluation by Doppler echocardiography in streptozotocin-induced diabetic rats. Vasc. Pharmacol. 2005, 43:91-100.
26. Lassegue B., Clempus R.E. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:277-297.
27. 2+-ATPase and myosin heavy chain isozyme switch. Diabetologia 2006, 49:1434-1446.
28. Li Z., Zhang T., Dai H., Liu G., Wang H., Sun Y., Zhang Y., Ge Z. Endoplasmic reticulum stress is involved in myocardial apoptosis of streptozocin-induced diabetic rats. J. Endocrinol. 2008, 196:565-572.
29. Li C.J., Zhang Q.M., Li M.Z., Zhang J.Y., Yu P., Yu D.M. Attenuation of myocardial apoptosis by alpha-lipoic acid through suppression of mitochondrial oxidative stress to reduce diabetic cardiomyopathy. Chin. Med. J. 2009, 122:2580-2586.
30. Li Y., Yao J.H., Hu X.W., Fan Z., Huang L., Jing H.R., Liu K.X., Tian X.F. Inhibition of Rho kinase by fasudil hydrochloride attenuates lung injury induced by intestinal ischemia and reperfusion. Life Sci. 2011, 88:104-109.
31. Lin G., Craig G.P., Zhang L., Yuen V.G., Allard M., McNeill J.H., MacLeod K.M. Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats. Cardiovasc. Res. 2007, 75:51-58.
32. Ma Z.H., Zhang J.P., Du R.P., Ji E.S., Chu L. Rho kinase inhibition by fasudil has anti-inflammatory effects in hypercholesterolemic rats. Biol. Pharm. Bull. 2011, 34:1684-1689.
33. Ma Z.H., Zhang J.P., Ji E.S., Cao G., Li G.M., Chu L. Rho kinase inhibition by fasudil exerts antioxidant effects in hypercholesterolemic rats. Clin. Exp. Pharmacol. Physiol. 2011, 38:688-694.
34. Mizushige K., Yao L., Noma T., Kiyomoto H., Yu Y., Hosomi N., Ohmori K., Matsuo H. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000, 101:899-907.
35. Nakagawa O., Fujisawa K., Ishizaki T., Saito Y., Nakao K., Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996, 392:189-193.
36. Oi K., Shimokawa H., Hiroki J., Uwatoku T., Abe K., Matsumoto Y., Nakajima Y., Nakajima K., Takeichi S., Takeshita A. Remnant lipoproteins from patients with sudden cardiac death enhance coronary vasospastic activity through upregulation of Rho-kinase. Arterioscler. Thromb. Vasc. Biol. 2004, 24:918-922.
37. Okutan H., Ozcelik N., Ramazan Yilmaz H., Uz E. Effects of caffeic acid phenethyl ester on lipid peroxidation and antioxidant enzymes in diabetic rat heart. Clin. Biochem. 2005, 38:191-196.
38. Rikitake Y., Kim H.H., Huang Z.H., Seto M., Yano K., Asano T., Moskowitz M.A., Liao J.K. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005, 36:2251-2257.
39. Sharma V., Parsons H., Allard M.F., McNeill J.H. Metoprolol increases the expression of β3-adrenoceptors in the diabetic heart: effects on nitric oxide signaling and forkhead transcription factor-3. Eur. J. Pharmacol. 2008, 595:44-51.
40. Shen X., Zheng S., Metreveli N.S., Epstein P.N. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006, 55:798-805.
41. Shimokawa H. Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn. Circ. J. 2000, 64:1-12.
42. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J. Cardiovasc. Pharmacol. 2002, 39:319-327.
43. Shiotani S., Shimada M., Suehiro T., Soejima Y., Yosizumi T., Shimokawa H., Maehara Y. Involvement of Rho-kinase in cold ischemia-reperfusion injury after liver transplantation in rats. Transplantation 2004, 2004(78):375-382.
44. Tomlinson K.C., Gardiner S.M., Hebden R.A., Bennett T. Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol. Rev. 1992, 44:103-150.
45. Toshima Y., Satoh S., Ikegaki I., Asano T., Dietrich W.D. A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 2000, 31:2245-2250.
46. Turdi S., Li Q., Lopez F.L., Ren J. Catalase alleviates cardiomyocyte dysfunction in diabetes: role of Akt, forkhead transcriptional factor and silent information regulator 2. Life Sci. 2007, 81:895-905.
47. Wang N., Guan P., Zhang J.P., Chang Y.Z., Gu L.J., Hao F.K., Shi Z.H., Wang F.Y., Chu L. Preventive effects of fasudil on adriamycin-induced cardiomyopathy: possible involvement of inhibition of RhoA/ROCK pathway. Food Chem. Toxicol. 2011, 49:2975-2982.
48. Wang N., Guan P., Zhang J.P., Li Y.Q., Chang Y.Z., Shi Z.H., Wang F.Y., Chu L. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses isoproterenol-induced heart failure in rats via JNK and ERK1/2 pathways. J. Cell. Biochem. 2011, 112:1920-1929.
49. Zhang C.H., Zang W.J., Xu J., Yu X.J., Lu J., Jing A.Y., Chen L.N., Hu H., Sun Q. A method to produce the animal model of diabetic cardiomyopathy. J. Hyg. Res. 2006, 35:703-708.
50. Zhou H., Li Y.J., Wang M., Zhang L.H., Guo B.Y., Zhao Z.S., Meng F.L., Deng Y.G., Wang R.Y. Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes. Acta Pharmacol. Sin. 2011, 32:999-1008.